Mechanism: An anti-inflammasome drug inhibits the NLRP3 inflammasome, reducing the production of inflammatory IL-1β particles and mitigating senescent cell-associated secretory phenotypes. Readout: Readout: This leads to a significant decrease in the 'Inflammation Score' and a projected '+25% Lifespan' increase.